Compare Gilead Sciences, Inc. (GILD) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Hims and Hers Health Inc — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while Hims and Hers Health Inc trades at $28.38 (market cap $6.55B). The key difference: Gilead Sciences, Inc. is far larger — about 27.8× Hims and Hers Health Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Hims and Hers Health Inc for 21 Days on average.
| GILD | HIMS | |
|---|---|---|
Market Cap | $182.40B | $6.55B |
Volume | 4,469,821 | 14,842,814 |
Sector | Health | Health |
52-Week High | $155.80 | $62.76 |
52-Week Low | $116.74 | $14.52 |
Typical Hold Time | 111 Days | 21 Days |
Enterprise Value | $205.46B | $7.25B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.
The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
